Enantuzumab’s estimated selling price in 2025

Elranatamab is an immunotherapy drug developed with bispecific antibody technology and is mainly used to treat relapsed or refractory multiple myeloma (RRMM). Although traditional treatments include chemotherapy, proteasome inhibitors, immunomodulators, and anti-CD38 monoclonal antibodies, many patients still experience disease relapse or drug resistance after multiple courses of treatment, which makes treatment more complicated.

Enatuzumab, as a bispecificB cell maturation antigen (BCMA)-directed CD3 T cell engager, activates the patient's T cells to recognize and attack multiple myeloma cells by simultaneously binding BCMA and CD3. This mechanism makes ernatumumab effective in overcoming the limitations of traditional therapies, especially in patients with relapsed or refractory multiple myeloma who have received at least four therapies. These therapies often include proteasome inhibitors, immunomodulators, and anti-CD38 monoclonal antibodies, but patients still fail to achieve adequate clinical responses.

Regarding the price, eractuzumab is already on the market in China, but it is not yet included in medical insurance, so patients may need to pay for it out of pocket. At present, the common specifications of eractuzumab are 44mg (1.1ml) and 76mg (1.9ml), and each box sells for about 40,000 yuan. Compared with foreign prices, the price of enantuzumab has decreased in the Chinese market, but it is still a relatively expensive drug. The selling price of the original drug in the U.S. market is approximately more than 8,000 US dollars. Due to the impact of exchange rates, the selling price in the international market may fluctuate.

Currently, there are no generic versions of Enactuzumab on the market, which also makes its price in the market relatively high. Over time, more competitors may enter the market, and the emergence of generic drugs may reduce the cost of treatment in the future, but currently the cost of treatment with this drug remains a challenge for patients and the health care system.

Reference materials:https://www.drugs.com/mtm/elranatamab.html